Voyager Therapeutics (VYGR) Price & Analysis

Compare

1,175 Followers

VYGR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.65 - $8.28

Previous CloseN/A

Volume91.62K

Average Volume (3M)751.85K

Market Cap

$189.70M

Enterprise Value$7.06M

Total Cash (Recent Filing)$215.59M

Total Debt (Recent Filing)$40.20M

Price to Earnings (P/E)5.0

Beta1.50

Next Earnings

Nov 18, 2025

EPS Estimate

-0.52

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding55,468,807

10 Day Avg. Volume619,154

30 Day Avg. Volume751,850

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.04

Enterprise Value/Revenue0.17

Enterprise Value/Gross Profit0.17

Enterprise Value/Ebitda-0.06

Forecast

1Y Price Target

$14.94

Price Target Upside336.84% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

Bulls Say, Bears Say

Bulls Say

Cash PositionWith $262 million in cash and a runway extended into 2028, analysts reiterate a Buy rating with key catalysts expected to drive meaningful upside.

PartnershipsThe company's gene therapy programs utilize its proprietary TRACER capsid technology, which has shown promise in that it has been the subject of several external partnerships.

Platform DifferentiationVoyager is seen as one of the most differentiated central nervous system platforms in development due to its Alzheimer’s and gene therapy pipeline.

Bears Say

Clinical Trials TimelinePartner NBIX remains on track for IND filings for GBA-1 gene therapy for Parkinson/Gaucher and FXN gene therapy by year-end 2025.

Dependency On MilestonesVYGR could receive up to $35 million in milestones from partnered programs entering the clinic.

High RiskThe company has several pipeline products targeting Alzheimer's Disease, which remains an area of high unmet need with high-risk/high-reward characteristics.

Voyager Therapeutics News

Voyager Therapeutics price target lowered to $8 from $9 at Wedbush

Wedbush lowered the firm’s price target on Voyager Therapeutics (VYGR) to $8 from $9 and keeps an Outperform...

22d ago

VYGR

Voyager Therapeutics reports Q2 EPS (57c), consensus (52c)

Reports Q2 revenue $5.2M, consensus $9.5M. “We firmly believe Voyager’s science has the potential to drive transformative neurotherapeutics,...

22d ago

VYGR

Voyager Therapeutics: Strategic Positioning and Promising Pipeline Drive Buy Rating

Sumant Kulkarni, an analyst from Canaccord Genuity, maintained the Buy rating on Voyager Therapeutics. The associated price target...

15d ago

VYGR

Voyager Therapeutics Extends Cash Runway to 2028

Voyager Therapeutics Inc. ( ($VYGR) ) has released its Q2 earnings. Here is a breakdown of the information...

16d ago

VYGR

Voyager Therapeutics: Strategic Restructuring and Pipeline Progress Underpin Buy Rating

Analyst Lili (Aurélie) Nsongo of Leerink Partners maintained a Buy rating on Voyager Therapeutics, with a price target...

21d ago

VYGR

Voyager Therapeutics: Strong Financial Position and Promising Pipeline Drive Buy Rating

TD Cowen analyst Phil Nadeau has maintained their bullish stance on VYGR stock, giving a Buy rating today....

22d ago

VYGR

Buy Rating for Voyager Therapeutics Driven by Promising Alzheimer’s Gene Therapy and Significant Share Price Potential

In a report released yesterday, Samantha Semenkow from Citi maintained a Buy rating on Voyager Therapeutics, with a...

1M ago

VYGR

Voyager Therapeutics continues expansion of its AD franchise

Voyager Therapeutics (VYGR) continued the expansion of its Alzheimer’s disease, AD, franchise with the introduction of a wholly-owned...

1M ago

VYGR

Voyager Therapeutics’ Promising Alzheimer’s Study: A Potential Game-Changer?

Voyager Therapeutics Inc. (($VYGR)) announced an update on their ongoing clinical study. Voyager Therapeutics Inc. is conducting a...

2M ago

VYGR

Voyager Therapeutics Approves Stock Plans at Annual Meeting

Voyager Therapeutics ( ($VYGR) ) has issued an update. At the annual meeting held on June 3, 2025,...

3M ago

VYGR

Oppenheimer Predicts Up to ~550% Jump for These 2 ‘Strong Buy’ Stocks

After a rocky start to the spring, Wall Street came roaring back in May. President Trump’s softened tariff...

3M ago

TVRD

VYGR

Voyager Therapeutics demonstrates ALPL receptor-mediated BBB transport

Voyager Therapeutics (VYGR) announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase, ALPL, to...

4M ago

VYGR

Voyager Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating

In a report released on May 6, Lili (Aurélie) Nsongo from Leerink Partners maintained a Buy rating on...

4M ago

VYGR

Voyager Therapeutics Reports Q1 2025 Financial Results

Voyager Therapeutics Inc. ( ($VYGR) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

VYGR

VYGR FAQ

What was Voyager Therapeutics Inc.’s price range in the past 12 months?

Voyager Therapeutics Inc. lowest stock price was $2.65 and its highest was $8.28 in the past 12 months.

What is Voyager Therapeutics Inc.’s market cap?

Voyager Therapeutics Inc.’s market cap is $189.70M.

When is Voyager Therapeutics Inc.’s upcoming earnings report date?

Voyager Therapeutics Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 81 days.

How were Voyager Therapeutics Inc.’s earnings last quarter?

Voyager Therapeutics Inc. released its earnings results on Aug 06, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.526 by -$0.044.

Is Voyager Therapeutics Inc. overvalued?

According to Wall Street analysts Voyager Therapeutics Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Voyager Therapeutics Inc. pay dividends?

Voyager Therapeutics Inc. does not currently pay dividends.

What is Voyager Therapeutics Inc.’s EPS estimate?

Voyager Therapeutics Inc.’s EPS estimate is -0.52.

How many shares outstanding does Voyager Therapeutics Inc. have?

Voyager Therapeutics Inc. has 55,468,807 shares outstanding.

What happened to Voyager Therapeutics Inc.’s price movement after its last earnings report?

Voyager Therapeutics Inc. reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.526. Following the earnings report the stock price went down -5.294%.

Which hedge fund is a major shareholder of Voyager Therapeutics Inc.?

Currently, no hedge funds are holding shares in VYGR

Voyager Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-37.26%

Trailing 12-Months

Asset Growth

-26.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Voyager Therapeutics Inc.

Voyager Therapeutics (VYGR) is a clinical-stage gene therapy company focused on developing innovative treatments for neurological diseases. The company leverages its proprietary adeno-associated virus (AAV) platform to create gene therapies that target conditions such as Parkinson's disease, Huntington's disease, and other disorders of the central nervous system. Voyager’s commitment to advancing gene therapies aims to provide transformative solutions for patients with unmet medical needs in the field of neurology.

Voyager Therapeutics (VYGR) Earnings & Revenues

Historic Earnings Reports

VYGR Stock 12 Month Forecast

Average Price Target

$14.94

▲(336.84% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","31":"$31","8.5":"$8.5","23.5":"$23.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,8.5,16,23.5,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.96,5.04,7.12,9.2,11.280000000000001,13.36,15.440000000000001,17.52,19.6,21.68,23.76,25.840000000000003,27.92,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.96,3.8815384615384616,4.803076923076923,5.724615384615385,6.646153846153846,7.567692307692307,8.489230769230769,9.41076923076923,10.332307692307692,11.253846153846155,12.175384615384615,13.096923076923076,14.018461538461537,{"y":14.94,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.96,3.0015384615384617,3.043076923076923,3.0846153846153848,3.126153846153846,3.167692307692308,3.209230769230769,3.250769230769231,3.292307692307692,3.333846153846154,3.375384615384615,3.416923076923077,3.4584615384615383,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.68,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.56,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.85,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.93,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >